Newly prescribed canagliflozin vs. GLP-1 agonists was linked to amputation in older adults with type 2 DM and CVD.

Newly prescribed canagliflozin vs. GLP-1 agonists was linked to amputation in older adults with type 2 DM and CVD.
Ann Intern Med. 2021 Jan 05;:
Authors: Hao Q, Guyatt G
Abstract
SOURCE CITATION: Fralick M, Kim SC, Schneeweiss S, et al. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812. 32843476.
PMID: 33395335 [PubMed - as supplied by publisher]

Source: Annals of Internal Medicine - January 5, 2021 Category: Internal Medicine Authors: Hao Q, Guyatt G Tags: Ann Intern Med Source Type: research